Home - ABOUT CSTONE - Milestones
Milestones
  • Company Profile
  • Management Team
  • Vision & Mission
  • Milestones
  • Investor
  • Contact Us
  • 2016
    March, 2016 – CStone commenced the process of the Series A-1 to A-3 rounds of financing which in aggregate raised approximately US$150 million.
    April, 2016 – CStone Suzhou was established in Suzhou China.
    2017
    October, 2017 – CStone Suzhou Translational Medicine Research Center was established and commenced operations.
    October, 2017 – Phase I clinical trial of full-length and fully-human PD-L1 (CS1001) was launched and the first patient was dosed in China.
    2018
    April, 2018 – CStone commenced the process of the Series B round of financing raising in aggregate approximately US$262 million, which was the largest of series B financing in the biopharmaceutical sector in China at the time.
    May to June, 2018 - Three mAbs enter Phase I clinical trials in Australia: the CTLA-4 inhibitor CS1002, PD-1-targeted CS1003, and MEK inhibitor CS3006.
    June, 2018 – CStone and Blueprint entered into the Blueprint Agreement concerning the clinical development and commercialization of avapritinib CS3007 (BLU-285), CS3008 (BLU-554) and CS3009 (BLU-667).
    June, 2018 – CStone and Agios entered into the Agios Agreement concerning the clinical development and commercialization of ivosidenib (CS3010, AG-120) in China, Hong Kong SAR, Macau SAR and Taiwan, as a monotherapy or in combination with other therapies.
    June, 2018 – CStone launched two Phase II clinical trails of CS1001 (PD-L1 antibody) in China for the treatment of patient with cHL and NKTL and the first patient was dosed.
    July, 2018 – The U.S. FDA approved TIBSOVO (ivosidenib), a product developed by Agios to cure adult patients with relapsed or refractory acute myeloid leukemia.
    August, 2018 – CStone received IND approval from the NMPA for clinical trials in China of CS1002, a CTLA-4 monoclonal antibody developed by the company.
    August, 2018 – The CTA approval from the NMPA for Phase III (AGILE) global studies of TIBSOVO (ivosidenib), a product developed by the Agios, was received.
    October, 2018 – CStone launched a Phase III clinical trial of CS1001 in combination with standard-of-care therapy in China for the treatment of patients with Stage III NSCLC.
    October, 2018 – CStone initiated a Phase I clinical trial of CS3006 (MEK inhibitor) as single agent in patients with solid tumors in China.